PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home » Dissociative Identity Disorder

Consultant. Vol. 51 No. 3
Pages: 1  2  
Previous
 

Chronic Fatigue Syndrome:

An Update on Treatment in Primary Care

By Hani Raoul Khouzam, MD, MPH
University of California, San Francisco | March 8, 2011
Dr Khouzam is medical director, staff psychiatrist, and interim chief, chemical dependency treatment program, Veterans Affairs Central California Health Care System, Fresno, Calif. He is also health sciences clinical professor of psy­chiatry, University of California, San Francisco, Medical School, Medical Education Program, Fresno, Calif; and is clinical instructor in medicine at Harvard Medical School in Boston.

TREATMENT OF CO-OCCURRING CONDITIONS

Co-occurring medical or psychiatric conditions can contribute to a poor prognosis. Thus, it is important to diagnose and treat conditions that could aggravate symptoms of CFS. Although patients with CFS are often reluctant to consider a psychiatric cause of their symptoms, co-occurring psychiatric conditions need to be treated.7,10,15

Depression. For patients with mild to moderate depression, the options include CBT, antidepressant medication, or both.15 The choice of an antidepressant depends on the type of depression, the presence of symptoms such as pain or sleep disturbance, and any adverse effects of the medication that may exacerbate existing CFS symptoms. Psychiatric consultation is indicated for patients who have severe or chronic depression; suicidal intentions, especially when these coexist with social isolation; poor symptom control; or financial, interpersonal, and social difficulties.

Among the antidepressants that have been used in this setting are tricyclic antidepressants (TCAs), such as amitriptyline(Drug information on amitriptyline), desipramine, and nortriptyline; the selective serotonin reuptake inhibitors (SSRIs) fluoxetine, paroxetine, and sertraline; the serotonin norepinephrine(Drug information on norepinephrine) reuptake inhibitors (SNRIs) venlafaxine and duloxetine(Drug information on duloxetine); and other antidepressants, such as trazodone, mirtazapine(Drug information on mirtazapine), and bupropion. The SNRIs duloxetine and milnacipran, which have an FDA-approved indication for treatment of fibromyalgia, may ameliorate CFS symptoms of fatigue, body achiness, and pain.16

The enhanced sense of well-being that results from alleviation of the depressed mood may decrease the degree of fatigue in patients with CFS. Certain antidepressants, especially trazodone and mirtazapine, may also play a role in improving sleep. The TCAs may also relieve associated pain.

Anxiety. A common practice has been to prescribe antianxiety medications, especially the benzodiazepines, to treat the co-occurrence of anxiety disorders in patients with CFS. Because most SSRIs and SNRIs can alleviate anxiety symptoms associated with CFS, it is advisable to use these agents instead of the benzodiazepines. If benzodiazepines are prescribed, discussion and education about the benefits of these agents versus their potential for dependence and possible addiction would be warranted.

Sleep disturbances. The first line of treatment consists of sleep hygiene techniques, such as regulating times of going to bed and getting up; relaxing rather than sleeping during the day; and controlling noise, light, and temperature in the sleeping environment. If these strategies are not effective, the possibility of an underlying sleep disorder should be considered. A low dose of an antidepressant such as amitriptyline, trazodone, or mirtazapine may be indicated.17

Difficulty in initiating sleep can be temporarily managed with a short course of a hypnotic medication, such as the benzodiazepine temazepam(Drug information on temazepam) or flurazepam(Drug information on flurazepam), or a nonbenzodiazepine sedative-hypnotic, such as zolpidem, zaleplon, or eszopiclone. The nonbenzodiazepine sedative-hypnotics pose less risk of daytime confusion and morning hangover and may be safer than benzodiazepines, although they can cause other problems, including dissociative phenomenon and addiction. Even short-acting hypnotic agents may increase the risk of nighttime falling, cognitive difficulties, and confusion. In some patients with CFS who have severe and persistent sleep disturbances, the melatonin agent ramelteon has been helpful in initiating and maintaining sleep. Frequent monitoring of the adverse effects and duration of use of hypnotic medications is necessary to prevent the development of dependence and addiction.

Pain. Acetaminophen and NSAIDs, such as aspirin and ibuprofen(Drug information on ibuprofen), may be helpful in reducing pain and fever. The antiepileptics phenytoin, gabapentin(Drug information on gabapentin), and divalproex sodium(Drug information on divalproex sodium) may be useful, especially in patients who have neuropathic pain. Pregabalin can also be used in this setting. Muscle relaxants (eg, cyclobenzaprine(Drug information on cyclobenzaprine)) and antispasmodics (eg, baclofen(Drug information on baclofen)) or naproxen(Drug information on naproxen) may be helpful in patients who have painful muscle spasms. Because all these medications can have adverse effects, careful monitoring is warranted.

The use of opiates for pain associated with CFS is not recommended in a primary care setting; if these agents are indicated, refer the patient to a pain management specialist. Transcutaneous electrical nerve stimulation could be considered as an additional intervention for pain relief in some patients with CFS.7,15,17

Allergy-like symptoms. Antihistamines and decongestants that contain pseudoephedrine(Drug information on pseudoephedrine) may relieve allergy-like symptoms. However, the adverse effects associated with these medications warrant their cautious use, especially because they may contribute to increased fatigue.14,17,18

Hypotension. Medications such as fludrocortisone(Drug information on fludrocortisone) and midodrine(Drug information on midodrine) may be useful for the treatment of neurally mediated hypotension in patients with CFS.19

Additional Resources
for Primary Care Practitioners


Books

• Firestein GS, Budd RC, Harris ED Jr, et al, eds. Kelley’s Textbook of Rheumatology. 8th ed. Philadelphia: Saunders Elsevier; 2008.

• Jason LA, Fennell PA, Taylor RR, eds. Handbook of Chronic Fatigue Syndrome. Hoboken, NJ: John Wiley and Sons, Inc; 2003.

• Khouzam HR, Tan DT, Gill TS, eds. Handbook of Emergency Psychiatry. Philadelphia: Mosby Elsevier; 2007.

• Rakel P, ed. Conn’s Current Therapy. 58th ed. Philadelphia: WB Saunders; 2006.


Other publications

• Recognition and Management of Chronic Fatigue Syndrome:
Resource Guide for Health Care Professionals.
2006. Centers for Disease
Control and Prevention; 1600 Clifton Rd, Atlanta, GA 30333, USA
Tel: 404-639-3311, CDC Contact Center: 800-CDC-INFO , 888-232-6348 (TTY).


Associations

• American Association for Chronic Fatigue Syndrome, c/o Harborview Medical Center, 325 Ninth Avenue, Box 359780, Seattle, WA 98104

• The Chronic Fatigue Immune Dysfunction Syndrome Association of America, PO Box 220397, Charlotte, NC 28222-0398; Phone: 800-442-3437;
Fax: 704-365-2343; E-mail: cfids@cfids.org

• The National ME/FM Action Network, 3836 Carling Avenue,
Nepean, Ontario, Canada K2K 2Y6; Phone/Fax: 613-829-6667;
E-mail: ag922@freenet.carleton.ca


Internet resources

• Chronic Fatigue Immune Dysfunction Syndrome (CFIDS) Association of America  http://www.cfids.org

• The ME and CFS Information Page  http://www.cfids-me.org

• National ME/FM Action Network  http://www3.sympatico.ca/me-fm.action/main.html

 

CONTROVERSIAL AND EXPERIMENTAL THERAPIES

The following interventions should not be used to treat CFS unless co-occurring conditions exist to warrant their use.

CNS stimulants. These medications, such as methylphenidate(Drug information on methylphenidate), which are commonly used to treat attention-deficit/hyperactivity disorder (ADHD), could reduce fatigue and improve mental concentration in some patients with ADHD and CFS; however, CNS stimulants are not recommended for those who do not have ADHD.15,20 Modafinil—which is FDA-approved for treatment of narcolepsy, obstructive sleep apnea, and shift work sleep disorder—can increase wakefulness in patients with excessive daytime sleepiness and secondary fatigue, but it does not decrease fatigue in patients with CFS.21

D-Ribose. Although some trials found that natural D-ribose supplements may significantly ameliorate symptoms of CFS—with particular benefit in participants’ energy level and overall sense of well-being—the use of D-ribose is not recommended in a primary care setting.22

Hormonal treatment. Some studies have found that glucocorticoids, such as hydrocortisone(Drug information on hydrocortisone), and mineralocorticoids, such as fludrocortisone, may improve symptoms of CFS. In contrast, other studies found no benefit and showed only that hydrocortisone was effective in correcting underlying hypocortisolemia. Estradiol(Drug information on estradiol) patches and cyclical progestogens did decrease fatigue in CFS patients who had estrogen deficiency.23 Thyroid hormones, such as thyroxine, have no effect on the symptoms of CFS. Patients with comorbid hypothyroidism who received thyroid hormone experienced improvement in their daily functioning, which indirectly enhanced their ability to cope with fatigue related to CFS.

Cholinesterase inhibitors. These agents, such as donepezil(Drug information on donepezil), galantamine, and rivastigmine, which slow the progression of cognitive decline in Alzheimer disease, are not effective for the treatment of CFS.15,24

ALTERNATIVE AND COMPLEMENTARY THERAPIES

Acupuncture. This modality, which has been studied as a treatment for fatigue associated with fibromyalgia, has been reported to relieve coexisting pain and headache in some patients with CFS. Whether to recommend acupuncture for CFS patients in a primary care setting remains a controversial issue.25

Supplemental agents. Numerous self-help books and Web sites provide confusing and conflicting information to patients about the value of dietary changes and the use of various vitamin and mineral supplements and other products. There is little evidence to support most of these claims, and further lifestyle restrictions may impose greater financial and social burdens on patients.

Lentinan, beta carotene, high-dose vitamin B12, liver extract, folic acid(Drug information on folic acid), magnesium sulfate(Drug information on magnesium sulfate), essential fatty acids (eg, primrose oil and fish oil), and eicosapentaenoic acid (an omega-3 fatty acid supplement) have all been reported as effective treatments for CFS; however, none of these agents have undergone rigorous scientific testing.26 Despite limited data that suggest supplements such as carnitine and nicotinamide(Drug information on nicotinamide) adenine dinucleotide may have some value in reducing physical fatigue, expensive vitamin and mineral supplements are generally not recommended and megadose products should be avoided.10,26

Looking to the future. Recent evidence of and controversies on the role of xenotropic murine leukemia virus-related virus (XMRV) in the blood of persons with CFS has attracted considerable interest in the possibility of finding treatment or possibly discovering a vaccine to prevent CFS. However, the relevance and significance of XMRV to CFS still remain unclear.27

Pages: 1  2  
Previous
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






REFERENCES:

1. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121:953-959.
2. Carruthers BM, Jain AK, De Meirleir KL, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chron Fatigue Syndrome. 2003;11:7-36.
3. Matsuda Y, Matsui T, Kataoka K, et al. A two-year follow-up study of chronic fatigue syndrome comorbid with psychiatric disorders. Psychiatry Clin Neurosci. 2009;63:365-373.
4. Gunn WJ, Connell DB, Randall B. Epidemiology of chronic fatigue syndrome: the Centers for Disease Control Study. Ciba Found Symp. 1993;173:83-93; discussion 93-101.
5. Cho HJ, Menezes PR, Hotopf M, et al. Comparative epidemiology of chronic fatigue syndrome in Brazilian and British primary care: prevalence and recognition. Br J Psychiatry. 2009;194:117-122.
6. Harvey SB, Wadsworth M, Wessely S, Hotopf M. Etiology of chronic fatigue syndrome: testing popular hypotheses using a national birth cohort study. Psychosom Med. 2008;70:488-495.
7. Shepherd C. The debate: myalgic encephalomyelitis and chronic fatigue syndrome. Br J Nurs. 2006;15:662-669.
8. Scheeres K, Wensing M, Severens H, et al. Determinants of health care use in chronic fatigue syndrome patients: a cross-sectional study. J Psychosom Res. 2008;65:39-46.
9. Shepherd C. Pacing and exercise in chronic fatigue syndrome. Physiotherapy. 2001;87:395-396.
10. Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry. 2003;160:221-236.
11. Deale A, Husain K, Chalder T, Wessely S. Long-term outcome of cognitive behavior therapy versus relaxation therapy for chronic fatigue syndrome: a 5-year follow-up study. Am J Psychiatry. 2001;158:2038-2042.
12. Prins JB, Bleijenberg G, Bazelmans E, et al. Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. Lancet. 2001;357:841-847.
13. Roth AD, Pilling S, Turner J. Therapist training and supervision in clinical trials: implications for clinical practice. Behav Cogn Psychother. 2010;38:291-302.
14. Chambers D, Bagnall AM, Hempel S, Forbes C. Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review. J R Soc Med. 2006;99:506-520.
15. Pae CU, Marks DM, Patkar AA, et al. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opin Pharmacother. 2009;10:1561-1570.
16. Kranzler JD, Gendreau RM. Role and rationale for the use of milnacipran in the management of fibromyalgia. Neuropsychiatr Dis Treat. 2010;25:197-208.
17. Neu D, Cappeliez B, Hoffmann G, et al. High slow-wave sleep and low-light sleep: chronic fatigue syndrome is not likely to be a primary sleep disorder. J Clin Neurophysiol. 2009;26:207-212.
18. Lyall M, Peakman M, Wessely S. A systematic review and critical evaluation of the immunology of chronic fatigue syndrome. J Psychosom Res. 2003;55:79-90.
19. Wyller VB, Thaulow E, Amlie JP. Treatment of chronic fatigue and orthostatic intolerance with propranolol. J Pediatr. 2007;150:654-655.
20. Blockmans D, Persoons P, Van Houdenhove B, Bobbaers H. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? Am J Med. 2006;119:167.e23-e30.
21. Kumar R. Approved and investigational uses of modafinil: an evidence-based review. Drugs. 2008;68:1803-1839.
22. Teitelbaum JE, Johnson C, St Cyr J. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J Altern Complement Med. 2006;12:857-862.
23. Veldman J, Van Houdenhove B, Verguts J. Chronic fatigue syndrome: a hormonal origin? A rare case of dysmenorrhea membranacea. Arch Gynecol Obstet. 2009;279:717-720.
24. Madill PV. Chronic fatigue syndrome and the cholinergic hypothesis. JAMA. 2004;292:2723; author reply 2723.
25. Lijue Z. Acupuncture and Chinese patent drugs for treatment of chronic fatigue syndrome. J Tradit Chin Med. 2005;25:99-101.
26. Vermeulen RC, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Psychosom Med. 2004;66:276-282.
27. Menéndez-Arias L. Evidence and controversies on the role of XMRV in prostate cancer and chronic fatigue syndrome. Rev Med Virol. 2011;21:3-17.

Acknowledgments: The author thanks the VA Medical Center director, Mr Al Perry, FACHE, for his leadership and the chief of staff, Dr Wessel Meyer, for his support; Drs Robert Hierholzer, Nestor Manzano, Scott Ahles, and Craig C. Campbell, for their clinical guidance; Dr Avak A. Howsepian for his constructive criticism; Matthew Battista, PhD, and Leonard Williams, PA, for their encouragement; and Ms Ruth A. Cowell for her secretarial assistance.


 
RELATED TOPICS

Antisocial personality disorder
Borderline personality disorder
Compulsive personality disorder
Dependent personality disorder
Dissociative identity disorder
Histrionic personality disorder
Paranoid personality disorder
Passive-aggressive personality disorder
Schizotypal personality disorder
Schizoid personality disorder
Obsessive-compulsive neuroses


 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Developmental Psychopathology Comes of Age
  • Grief and Depression: The Sages Knew the Difference
  • The Moral Struggles of Practicing Psychiatrists
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Developmental Psychopathology Comes of Age
  • Psychiatry and the Myth of “Medicalization”
  • An Update on ADHD
  • Eco-Psychiatry: Why We Need to Keep the Environment in Mind
  • DSM-5: Where Do We Go From Here?
  • Suicidal Behavior: A Separate Diagnosis
  • New Insight Into the Neurobiology of Depression
  • Cultural Psychiatry and the 'No-Chicken' Doctor
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • Diagnosis and its Discontents: The DSM Debate Continues
  • Lamotrigine for Major Depressive Disorder Is Inappropriate
  • Psychiatry and the Myth of “Medicalization”
  • Parity Laws: Powerful Weapon—or Pipe Dream?
  • The Moral Struggles of Practicing Psychiatrists
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • NIMH vs DSM 5: No One Wins, Patients Lose
Click here to subscribe to our newsletter
 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry
 
CME
Current Clinical Practice in Asperger Disorder
Distinguishing Features of Borderline Personality Disorder and Bipolar Disorder—Clinical Diagnosis and Treatment


 
SEARCH MEDICA

Find peer-reviewed literature and websites for practicing medical professionals

CME on Dissociative Identity
Evidence on Dissociative Identity
Guidelines on Dissociative Identity
Patient Education on Dissociative Identity
Clinical Trials on Dissociative Identity
Practical Articles on Dissociative Identity
Research and Reviews on Dissociative Identity
All "Dissociative Identity" results


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy